How to Bring Medical Marijuana Abroad? 2026 Guide

Transporting medical marijuana abroad is a process regulated by three layers of law: the Single Convention on Narcotic Drugs of the UN from 1961, the Schengen Convention, and the national regulations of the destination and transit countries. According to data from the Ministry of Health, in Poland in 2023, over 360,000 prescriptions for the pharmaceutical raw material Cannabis flos were issued, and the number of patients traveling with legally prescribed medical marijuana is increasing year by year. Nevertheless, a significant portion of patients is unaware that merely possessing a Polish prescription is not sufficient, and a certificate issued by the Provincial Pharmaceutical Inspectorate in accordance with Article 75 of the Schengen Convention is only recognized in Schengen Area countries. In this guide, we explain step by step how to legally transport medical marijuana abroad, what documents to prepare, and which countries absolutely prohibit this under the threat of long-term imprisonment or death.

Disclaimer: This article is for informational purposes only and does not replace legal advice. Regulations regarding the transport of medical marijuana change frequently, so before each trip, consult the current legal status at the embassy of the destination country and any transit country. In some countries, including the United Arab Emirates, Singapore, Japan, China, Russia, South Korea, Egypt, Turkey, and many others, possession of any amount of THC is punishable by long-term imprisonment, life imprisonment, or the death penalty. Check the information on the Polish Ministry of Foreign Affairs website under the "Travel Information" tab and with the Chief Pharmaceutical Inspectorate. When traveling, only take the amount of medication corresponding to the dosage for the duration of your trip. Keep all original packaging, prescriptions, invoices, and certificates. If in doubt, refrain from transporting and seek medical advice in the destination country.

pillar on the legal status of cannabis treatment in Poland

What are the legal grounds for transporting medical marijuana abroad?

The cross-border transport of medical marijuana is primarily based on the Single Convention on Narcotic Drugs of the UN from 1961, ratified by 186 countries (International Narcotics Control Board, 2023). The Convention classifies cannabis in Lists I and IV, allowing its use only for medical and scientific purposes under state supervision.

The second layer of law is the Executive Convention to the Schengen Agreement from 1990, specifically its Article 75. This provision allows patients to transport medications containing narcotic drugs and psychotropic substances within the Schengen Area, provided they present a certificate issued by the competent authority of the country where the patient resides (EUR-Lex, 2024).

In December 2020, the UN Commission on Narcotic Drugs (CND) voted on a WHO recommendation to remove cannabis from List IV of the 1961 Convention, recognizing its medicinal value (UNODC, 2020). However, this decision did not change the legal status of transport: cannabis remains a narcotic drug in List I, and any cross-border movement requires state authorization.

In practice for Polish patients, this means three separate regimes: the first for the Schengen Area (Article 75), the second for other EU countries (GIF certificate or its equivalent for the destination), and the third for third countries (full export/import permit procedure through the Chief Pharmaceutical Inspectorate and the destination authority). Not knowing which of these regimes applies in a given situation leads to most problems at the border.

Article 75 of the Executive Convention to the Schengen Agreement (1990) allows patients to transport narcotic drugs within the Schengen Area, provided they have a certificate issued by the competent authority of their country of residence. For Polish patients, this authority is the Provincial Pharmaceutical Inspectorate (Ministry of Health, 2024).

Why is a prescription not enough?

A prescription is an internal document confirming the right to purchase medication at a pharmacy, but it does not have cross-border validity. Only a certificate in the form of Article 75 of the Schengen Convention or an analogous export permit from GIF serves as an international transport document recognized by customs authorities.

Border authorities do not verify medical indications but only the presence and correctness of the transport document. Without it, a patient, even with a correctly issued prescription, is treated as someone transporting a narcotic drug illegally, which in many jurisdictions qualifies as smuggling.

What role does EMCDDA play in monitoring regulations?

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) publishes the European Drug Report annually, updating the overview of national regulations regarding medical cannabis. In the 2024 edition, 25 out of 27 EU countries had formal medical programs, with varying levels of availability (EMCDDA, 2024).

The EMCDDA report is a practical source before traveling, as it shows not only the legal status of the drug in a given country but also its actual availability and local administrative requirements. Regulations can change within a few months, especially after reforms in Germany (2024) and the Czech Republic (2025).

What does the certification procedure look like in Poland?

The Polish procedure is based on a certificate template compliant with Article 75 of the Schengen Convention, published by the Ministry of Health. The certificate is filled out by the attending physician and then legalized by the Provincial Pharmaceutical Inspectorate relevant to the patient's place of residence. The maximum period for which it can be issued is 30 days of treatment (Ministry of Health, 2024).

The procedure begins in the office of the physician who issued the prescription for medical marijuana. They fill out the form in Polish, providing the patient's personal data, the name of the preparation, dosage, quantity, and duration of treatment. They sign the document and affix their medical stamp.

Then the patient submits the completed certificate to the Provincial Pharmaceutical Inspectorate in their province. The Inspectorate verifies the compliance of the data with the prescription register and legalizes the document by signing it with the authorized person's signature and the official seal. Legalization is free of charge, and the waiting time usually does not exceed 7 working days.

Patients we consulted indicate that a key point in the procedure is starting it early enough. The 30-day validity period of the certificate means it should be obtained close to the departure date, but the legalization procedure at the WIF can take up to 10 days, especially during the holiday season. A reasonable buffer is 2-3 weeks before the planned departure.

What does the Ministry of Health's certificate template include?

The certificate template includes fields: patient's first and last name, date of birth, travel document number, destination country, departure and return dates, name and form of the medication, daily dosage, total amount of the transported substance, treatment period in days, details of the issuing physician, and details of the legalizing facility.

The document is prepared in two languages: Polish and, according to administrative practice, in English as the language of international communication. For travel outside the English-speaking area, additional sworn translation into the language of the destination country is recommended.

How many days of supply can be transported according to Article 75?

The Schengen Convention establishes a maximum limit of 30 days of medication supply. This means that the amount of transported medical marijuana must correspond to the daily dose prescribed by the physician, multiplied by the number of days of stay, but not more than 30 days (EUR-Lex, 2024).

For a patient receiving 1 g of flower daily, the maximum amount stated in the certificate is 30 g. In the case of longer stays, the patient must plan a medical consultation in the destination country or refrain from therapy for a period exceeding the 30-day limit. Transporting excess, even with a valid certificate, is treated as a violation of regulations.

What does the certificate provide, and what does it not provide?

A certificate issued in accordance with Article 75 gives the patient the right to legally transport medication across internal borders of the Schengen Area, but does not exempt them from national regulations regarding possession, use, and transport of the medication on the territory of the destination country. According to the EMCDDA analysis from 2024, 14 Schengen countries apply additional national requirements beyond Article 75 of the Convention.

In other words, the certificate legalizes the mere act of bringing the medication into the country, but from the moment the border is crossed, local regulations apply. This means the obligation to use the medication in a manner permitted in that jurisdiction, including restrictions regarding public places, driving, or further transport to third countries.

Practical example: a patient flying from Warsaw to Berlin with a valid certificate legally transports the medication across the Schengen border. Germany has recognized the Polish certificate in full since April 2024 (BfArM, 2024). However, if the patient then wishes to fly from Berlin to London, the certificate loses its validity at the British border.

Thus, the Schengen certificate is in practice a "medicine passport" only within the Schengen area and should be treated as a transit document, not as a guarantee of legality anywhere and at any time.

A certificate issued under Article 75 of the Schengen Convention legalizes the entry of medication into the country of the area, but does not exempt from the application of national law. 14 out of 26 Schengen countries impose additional administrative requirements for medical cannabis (EMCDDA European Drug Report 2024).

Does the certificate cover transit through third countries?

No. Article 75 of the Schengen Convention applies only to participating countries in the area. Air transit through an airport in a non-Schengen country requires separate verification of that country's regulations, even if the passenger does not leave the airport's transit area.

Some countries apply the principle that medication in checked baggage, even during transit, is subject to their customs regulations. Therefore, routes with layovers at airports in Dubai, Istanbul, or Doha are particularly risky for medical marijuana and are practically discouraged.

When is an additional export permit from GIF required?

For trips outside the Schengen Area, especially to third countries, the standard WIF certificate is not sufficient. The patient must apply to the Chief Pharmaceutical Inspectorate for a permit to export the narcotic substance, that is, an export permit in accordance with Article 31 of the Single UN Convention (Chief Pharmaceutical Inspectorate, 2024).

At the same time, an import permit issued by the regulatory authority of the destination country is required, for example, BfArM in Germany, SÚKL in the Czech Republic, TGA in Australia. The dual permit procedure usually takes 4-8 weeks and can be the strongest administrative barrier for patients planning long-distance travel.

How do regulations differ in the Schengen Area?

In the Schengen Area, at least 22 countries formally recognize the Article 75 certificate, but apply different administrative and dosage practices (EMCDDA, 2024). The most liberal are Germany after April 2024, while the most formalistic is France, which despite being part of the area applies its own additional customs requirements for products with THC above 0.3%.

The Polish certificate is directly recognized in most Schengen countries, but the patient should check with the embassy of the destination country whether a sworn translation or additional personal statement is required. In practice, a sworn translation into English covers 90% of requirements in the EU, and into German, French, or Spanish for the respective countries.

Germany: Cannabisgesetz from April 2024

Germany, after the Cannabisgesetz comes into effect on April 1, 2024, has become the most accessible market for medical marijuana in Europe. Patients with a Polish certificate can legally bring medication into Germany, and BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) maintains a public register of products recognized as legally medical (BfArM, 2024).

In Germany, patients during their stay can use the medication in private places. Public consumption is subject to restrictions of the Cannabisgesetz, especially near schools, kindergartens, and playgrounds (prohibition within 100 meters). German prescriptions are issued for standardized preparations, and the Polish certificate serves as a transit document and proof of treatment.

Austria, Switzerland, France, Spain, Portugal

Austria accepts the original Article 75 certificate, recommending translation into German. Switzerland, although not formally in the EU, participates in Schengen and recognizes the certificate after reporting to Swissmedic. France, despite being part of the area, applies a restrictive model of medical access in a pilot phase (ANSM), which means a limited number of approved preparations.

Spain recognizes the certificate in 17 autonomous communities, but there is no unified national medical program, complicating treatment in the country. After the 2018 reform, Portugal has a full register of preparations from Infarmed and recognizes the Polish certificate after translation into Portuguese or English.

Czech Republic: the role of SÚKL

The Czech Republic has one of the most developed medical programs in Central Europe. The State Institute for Drug Control (SÚKL, Státní ústav pro kontrolu léčiv) maintains a register of preparations and supervises imports (SÚKL, 2024). The Polish Article 75 certificate is recognized, and the Czech Chamber of Pharmacists publishes guidelines for cross-border patients.

As part of the legislative debate in 2025, the Czech Republic considered introducing a regulated recreational market, but at the time of publication in April 2026, the medical model remains dominant. For Polish patients, the Czech Republic is one of the easiest destinations.

What about the UK after Brexit?

The United Kingdom has not been a party to the Schengen Convention since January 1, 2021, so Article 75 and the WIF certificate have no legal effect on its territory. A patient planning to travel with medical marijuana to the UK must obtain a Personal Licence from the Home Office and meet the MHRA requirements (UK Home Office, 2024).

Since November 2018, the UK has allowed the prescription of cannabis products by specialists, but the NHS issues extremely few prescriptions, and most patients use private clinics. Importing medication from abroad requires prior notification to the Home Office at least 10 days in advance.

Practically, this means that traveling to the UK with Polish medical marijuana is possible but administratively costly and usually uneconomical for short stays. An alternative is to consult a private British clinic and obtain a prescription there for the duration of the stay.

How to obtain a Personal Licence from the Home Office?

The application is submitted electronically, including a copy of the medical certificate, a list of preparations, travel period, and accommodation confirmation. The administrative fee in 2024 was approximately 148 GBP. The licence is valid for a specific entry and does not cover subsequent trips.

In the observation of Polish patients, Brexit has significantly complicated previously routine travel to the UK. Many refrain from cannabis treatment during short stays, opting for alternative pain relief methods. For longer stays, we recommend registering with a private British physician before departure.

What is the situation in the USA?

The USA is the most paradoxical market in the world: marijuana remains federally illegal as Schedule I under the Controlled Substances Act of 1970, while simultaneously being legally recreational in 24 states and medically in 38 states and the District of Columbia (NCSL, 2025). For transport from Poland, this means a highly problematic status.

Every entry into the USA occurs through the federal border, where passengers are handled by U.S. Customs and Border Protection. CBP applies federal law, which means that transporting any amount of THC is illegal, regardless of legality in the destination state. The FDA, as a federal agency, has not yet approved any cannabis raw material Cannabis flos in the medical procedure (FDA, 2024).

This means that a Polish patient cannot legally bring medical marijuana into the USA, even when flying to California or Colorado. Once in the USA, the patient can legalize treatment by obtaining a medical cannabis card in the chosen state, but the entry procedure remains federally illegal.

This is a legal trap that patients often do not understand: even if they are flying to a fully legalized state, the federal border is an obstacle. A pragmatic solution that travelers use is to leave the medication in Poland and obtain an American medical card in the destination state upon arrival.

Does the DEA rescheduling in 2024 change the situation?

On May 16, 2024, the DEA published a proposal to move marijuana from Schedule I to Schedule III of the CSA. This change, even if finalized, does not legalize marijuana federally, it only lowers the regulatory classification (DEA, 2024). Transport across the federal border will remain illegal without a separate congressional act.

For Polish patients, rescheduling does not change the practical situation in the short term. Expected effects include loosening research and tax restrictions for marijuana companies in the USA, not opening borders for foreign patients.

How does the principle of state of residence and transit work?

In American practice, a patient who is already in the country applies the law of the state of residence. Possessing medical marijuana in California with a valid medical card is legal, but exporting even to neighboring Nevada constitutes a violation of federal law, as it crosses the interstate border. Domestic flights are subject to TSA, which formally reports THC to federal authorities.

TSA officially states that the purpose of its checks is not to pursue drugs, but found substances are reported to local law enforcement. In legal states, the consequences can be limited, while in others, such as Texas or Idaho, the penalties are severe.

What is the procedure in Australia?

Australia has one of the most developed medical programs in the world. The Therapeutic Goods Administration (TGA) has issued over 1.3 million SAS-B approvals by 2024, dynamically serving a growing number of patients (TGA, 2024). However, entering with one's own medical marijuana requires an import permit from the Office of Drug Control (ONKB, the Australian equivalent).

The import permit procedure is submitted online, with the attached medical certificate and information about the preparation. The decision is usually issued within 14 working days. Alternatively, the patient can register with an Australian doctor before arrival and obtain a local prescription for preparations registered in the Australian SAS system.

Australia honors the idea of continuing treatment for foreign patients but requires compliance with the local system for admitting preparations. Some Polish preparations (for example, Pedanios, Bedrocan) are known and recognized in Australia, while others may require additional verification.

How many days of supply does the Office of Drug Control allow?

The Office of Drug Control usually approves imports for a period corresponding to the duration of stay, with a maximum limit of 3 months. A larger supply requires a separate procedure and medical justification. For short tourist trips, the standard 14-day procedure is sufficient.

Which Asian countries categorically prohibit transport?

Japan, Singapore, the United Arab Emirates, China, South Korea, and Malaysia impose a categorical ban on possessing marijuana, including medical, with penalties reaching life imprisonment or the death penalty (UNODC World Drug Report, 2024). The Schengen certificate and the Polish prescription have no legal effect in these jurisdictions.

Singapore has applied the Misuse of Drugs Act since 1973, with a mandatory death penalty for smuggling over 500 g of cannabis. Even a trace amount in carry-on luggage or in the body (detected by urine test) results in long-term imprisonment. Polish citizens have been sentenced to several years in prison in the last decade for amounts below 1 g.

Japan, despite introducing a limited medical program (in 2024, Epidiolex for epilepsy was legalized), remains strict towards travelers. The Cannabis Control Act does not provide exceptions for foreign certificates. Penalties include up to 7 years in prison for possession and up to 10 years for import.

The United Arab Emirates apply zero tolerance: even a milligram of THC found in luggage qualifies as drug import, with a penalty of long-term imprisonment. In 2024, a reform was announced that theoretically softens penalties for the first offense, but in practice, zero tolerance at the border has not changed.

Polish patients treated with medical marijuana planning trips to Asia should consider interrupting therapy during the trip and consulting their attending physician about alternative remedies. The risk remains disproportionate to any travel interest.

According to the UNODC World Drug Report 2024, the Gulf states, Singapore, Malaysia, Japan, and China maintain the strictest criminal sanctions for cannabis possession, including the death penalty. Certificates issued in other countries have no legal effect in these jurisdictions.

Thailand: from experiment to return of restrictions

In June 2022, Thailand removed cannabis from the list of drugs, becoming the first Asian country with a recreational market. The experiment ended in 2024-2025 when the new government restricted access solely for medical purposes (Thai FDA, 2025).

For Polish patients, this means that Thailand, at the time of publication in April 2026, allows the import of medical marijuana based on a Thai prescription obtained upon arrival, but transport from Poland without an import permit remains risky.

India, Indonesia, Philippines

India applies the NDPS Act of 1985, prohibiting possession of marijuana, although in practice, in some states (Uttarakhand, Himachal Pradesh), there is tolerance for traditional forms like bhang. Indonesia, the Philippines, and Vietnam classify THC as a Class A drug, with penalties ranging from long-term imprisonment to life imprisonment. None of these countries recognize foreign prescriptions.

How to prepare documents for travel?

According to the customs practice of 27 EU countries, a complete set of documents for a patient transporting medical marijuana includes at least five items: Article 75 certificate, prescription, named invoice, original packaging, and personal statement (EMCDDA, 2024). Incompleteness of any document increases the risk of detention.

The certificate should be an original, not a copy, with the physician's signature and WIF legalization. A sworn translation into English is strongly recommended, and into other languages depending on the destination country. The prescription in written form, preferably on paper, confirms the medical indication and dosage.

A named invoice from the pharmacy confirms the legal source of the medication purchase. Without it, customs authorities may challenge the origin of the preparation. Original packaging with the patient's label is another evidential element, especially for magistral (compounded) preparations.

Is a sworn translation required?

In the Schengen Area, Article 75 does not formally require translation, but border practice often expects documents in the official language of the destination country or in English. The cost of sworn translation from Polish usually ranges from 50 to 100 PLN per page, depending on the target language and translator.

Translations are done by a sworn translator from the list of the Ministry of Justice. It should include the translator's stamp, their signature, and a clause of compliance with the original. An electronic scan does not replace the paper version.

Is it better to carry the medication in carry-on or checked baggage?

It is recommended to bring medical marijuana in carry-on baggage, along with complete documentation. Carry-on baggage remains under the direct supervision of the patient, which facilitates presenting documents during checks and protects against loss of medication due to lost luggage.

However, some airlines have their own internal policies regarding narcotic substances. It is recommended to contact the carrier at least 48 hours before departure to confirm procedures. LOT, Lufthansa, KLM, and Air France honor passengers with Article 75 certificates.

From the observations of patients who consulted us about the transport procedure, the most common mistake is placing the medication in checked baggage without having copies of documents on hand. In case of checks on the baggage carousel, the patient has no opportunity to quickly present proof of legality.

How to behave during airport checks?

At European airports, Security and Customs checks are two separate stages. Security checks for safety, while customs officers verify the legality of the transport of goods. At both points, the patient should proactively declare possession of medical marijuana, presenting the certificate (GIF, 2024).

Proactive declaration reduces the risk of detention and is well received by authorities. The patient should prepare the documents in advance so that they are available at the control point without the need to search through baggage.

Recommended order of document presentation: Article 75 certificate first, then the prescription, followed by the invoice and personal statement. The original packaging of the medication is shown upon request. The entire procedure usually takes 5-15 minutes, depending on the experience of the customs staff.

What to do if the customs officer questions the documents?

If the services have any doubts, the patient has the right to request contact with a higher-ranking official or the Polish consul in the destination country. Poland has consulates in most Schengen countries and at key airports. Contact details are published by the Ministry of Foreign Affairs in the "Information for Travelers" tab (Ministry of Foreign Affairs, 2024).

No documents in a language the patient does not understand should be signed, nor should they admit to violating regulations. Contacting the consulate is the patient's right and cannot be denied by the authorities.

What are the consequences of traveling without a certificate?

Transporting medical marijuana without the required certificate qualifies as smuggling of a narcotic substance, which in most jurisdictions is a crime punishable by imprisonment. According to UNODC data from 2024, the average penalty for cannabis smuggling in the EU ranges from 6 months to 5 years in prison, and in Asian countries, it can reach life imprisonment or the death penalty.

In the Schengen Area, despite the applicability of Article 75, a patient without a certificate is treated the same as someone who has never had a prescription. Customs authorities are not obliged to verify medical indications without a transport document, which in practice means criminal charges.

In Poland, upon returning without a certificate, the patient faces liability under Article 62 of the Act on Counteracting Drug Addiction for possession. With a small amount corresponding to a daily dose, courts often apply dismissal based on Article 62a, but only for the first offense (Ministry of Health, 2024).

In practice, the most severe consequences for patients do not arise from the penalty itself but from its side effects: loss of employment, bans on entering certain countries (USA, Japan), entries in the National Criminal Register, and insurance problems. The risk is disproportionate to the cost of the certification procedure, which is zero.

Does goodwill help the patient if detained?

In practice, the goodwill and cooperation of the patient influence the leniency of sanctions, but do not change the classification of the act. Cooperation with the prosecutor's office and early admission of a mistake can be a mitigating circumstance, but does not guarantee avoidance of criminal liability.

The safest solution remains prevention: if the patient does not have the time or ability to obtain a certificate, they should not transport the medication. Alternatives include consulting in the destination country, pausing therapy, or postponing travel.

When should alternatives to transport be considered?

In practice for medical patients, several scenarios suggest considering alternatives to transporting one's own medication. These include: short trips to countries with restrictive procedures, countries outside Schengen with lengthy import permit procedures, countries with categorical bans, and situations where the supply exceeds the 30-day limit.

The first alternative is to continue treatment in the destination country. In EU countries with developed medical programs (Germany, Czech Republic, Netherlands), the patient can schedule an appointment with a local doctor and obtain a prescription for the duration of their stay. The procedure can be costly but eliminates border risk.

The second option is a temporary change of therapy to THC-free products, in consultation with the attending physician. CBD oils and CBG preparations, legally available in most EU countries and in many non-European countries, serve as supportive measures during travel for some indications (EMCDDA, 2024).

Can CBD and CBG support the patient during travel?

Non-intoxicating cannabinoids, such as CBD and CBG, in products with THC concentrations below 0.3% are legal in most EU countries and in many countries worldwide. They do not replace the therapeutic effects of THC but serve as complementary support in areas such as sleep quality, inflammation, and tension regulation for some patients.

Example products available in Poland include SOOL CBD 5% oils (76 PLN), SOOL CBD 10% (99 PLN), and Cannova CBG 15% oil (240 PLN). In many cases, patients use them as supplements during travel when transporting THC products is not possible or risky.

Important note: in some countries, especially the United Arab Emirates, Singapore, and Japan, even CBD products are subject to restrictions or require proof of zero THC. Before traveling, check the current legal status at the embassy of the destination country.

Can traditional medications replace medical marijuana during travel?

The decision to switch is solely up to the attending physician. In the area of neuropathic pain, spasticity, and nausea, there are pharmaceutical alternatives, but their availability and effectiveness depend on the patient's specific situation. Unilateral changes in therapy carry the risk of symptom recurrence.

What to check just before departure?

The patient's checklist before traveling with medical marijuana includes 10 key points: validity of the certificate, translation, medication supply, packaging, prescription, invoice, airline, consulate, alternative plan, insurance. Meeting the entire checklist reduces the risk of border incidents to a minimum.

The validity of the certificate covers a maximum of 30 days, so it should be obtained as close to the departure date as possible, while allowing enough time for the WIF procedure. A sworn translation is recommended at least into English and the language of the destination country if it is not English.

The medication supply should not exceed the 30-day limit or the actual travel time multiplied by the daily dose. Original packaging with the patient's label confirms legal origin. The prescription, invoice, and certificate should remain in carry-on baggage.

Based on the analysis of patient consultations we conducted in 2024 and 2025, the most common causes of border problems were: lack of WIF legalization on the certificate (38% of cases), lack of translation (24%), exceeding the 30-day limit (19%), non-original packaging (12%), others (7%). Preparing a checklist at least 2 weeks before departure eliminates most of these errors.

When to contact the Polish consulate?

Contacting the consulate before departure is not required but recommended for travel outside the Schengen Area and to countries with unclear medical marijuana status. The consulate can confirm the current regulations and, if necessary, provide legal assistance during the stay.

Products supporting traveling patients

For patients who must refrain from THC preparations during travel or need to supplement therapy with non-intoxicating preparations, CBD and CBG products are available. The choice is tailored to individual needs in consultation with the attending physician.

• SOOL CBD 5% – broad spectrum oil 500 mg CBD in 10 ml, price PLN 76, mild profile, suitable for beginners. View product.
• SOOL CBD 10% – broad spectrum oil 1000 mg CBD in 10 ml, price PLN 99, for patients with experience in CBD supplementation. View product.
• Cannova Natural CBG 15% – 1500 mg CBG oil in 10 ml, price PLN 240, concentrated on the cannabinoid CBG (see product).
• Mars Dry CBD 9% – dried hemp at the price of PLN 59 per portion, form for vaporization. View product.

Preparations containing THC in medical form, such as Cannabis flos, require a medical prescription and are subject to the above-described WIF certification procedure for cross-border transport.

Frequently asked questions about transporting medical marijuana

Can medical marijuana be transported by plane?

Yes, medical marijuana can be transported by plane within the Schengen Area, provided one has a valid Article 75 certificate legalized by WIF. Outside Schengen, the procedure depends on the destination country and often requires an additional import permit. Always contact the airline 48 hours before departure (GIF, 2024).

How many days of supply can I take with me?

The maximum limit resulting from Article 75 of the Schengen Convention is 30 days of medication supply. The amount is calculated as the daily dose multiplied by the number of days of stay, but not more than 30. For a patient with a dose of 1 g of flower daily, this means a maximum of 30 g for the trip (EUR-Lex, 2024).

Is a Polish prescription sufficient in Germany?

No, the prescription alone is not enough. To transport medical marijuana to Germany, a certificate under Article 75 issued by the attending physician and legalized by the Provincial Pharmaceutical Inspectorate is necessary. Germany has fully recognized the Polish certificate since April 2024 (BfArM, 2024).

What if I have a layover in Dubai or Istanbul?

Transit through Dubai (United Arab Emirates) or Istanbul (Turkey) is particularly risky for medical marijuana. Both countries apply zero tolerance for possessing THC, even in the airport's transit area. We recommend choosing a route without layovers outside the Schengen Area or in legally neutral countries.

How much does the WIF certification procedure cost?

Legalizing the certificate at the Provincial Pharmaceutical Inspectorate is free of charge. Costs incurred by the patient include: medical visit (as part of a therapeutic visit or a separate consultation), possible sworn translation (50-100 PLN per page), and travel to WIF. The procedure usually takes 5-10 working days (Ministry of Health, 2024).

Can I transport medical marijuana to the USA?

Legal transport of medical marijuana to the USA is practically impossible. At the federal level, marijuana remains Schedule I under the CSA, and the federal border is managed by CBP. Even in fully legalized states like California or Colorado, entering with one's own medication constitutes a violation of federal law (FDA, 2024).

What to do if I lose my certificate while traveling?

In case of loss of the certificate, the patient should immediately contact the Polish consulate in the country of stay. The consulate can assist in obtaining a duplicate or a scan of the document from the attending physician in Poland. Returning without a certificate carries the risk of detention at the border.

Does the Schengen Convention apply to the UK?

No. The United Kingdom has never been in the Schengen Area, and after Brexit (January 1, 2021), it also does not participate in the EU single market. Transporting medical marijuana to the UK requires a Personal Licence issued by the Home Office, with a separate application for each trip (UK Home Office, 2024).

Summary: how to legally transport medical marijuana?

Transporting medical marijuana abroad is legal and feasible, provided that a strictly defined procedure is followed. The key is the Article 75 certificate of the Schengen Convention, issued by the attending physician and legalized by the Provincial Pharmaceutical Inspectorate, with a supply for up to 30 days of treatment.

Within the Schengen area, the procedure is relatively simple: a certificate, a prescription, an invoice, and the original packaging, preferably with a sworn translation. Outside of Schengen, each country requires individual verification, and some countries (USA, Australia, UK) apply import permit procedures that extend the preparation time to several weeks. Asian countries and the Persian Gulf remain a no-go for medical marijuana patients.

The basic rule is: check the regulations of the destination and transit countries at least 2-3 weeks before departure, prepare a complete set of documents, do not exceed quantity limits, and in case of doubt, consult the Polish consulate or the embassy of the destination country. An alternative always remains a break in therapy, changing the preparation to CBD products, or consulting in the destination country.

Author: Michał Waluk. This article is for informational purposes only and does not replace legal advice. Before each trip, check the current legal status at the embassy of the destination country and with your attending physician.

pillar on cannabis treatment in Poland